Danaher Corporation ·DHR

Three platform CEOs run Danaher’s core businesses

Healthcare · Fortune #100 · Divisional structure · 63K employees · Washington, DC

View as of:

CEO span

↓ tighter than peers (avg 10)

3.1

Avg span

moderate

Max depth

3 levels

3.6 yr

Avg tenure

stable vs FY2024

62%

Internal hires

↑ above industry avg

Consolidated financials FY2025 · period end 2025-12-31 · 10-K

Revenue

$24.6B

Operating income

$4.7B

Net income

$3.6B

Total assets

$83.5B

Shares out

707M

Sourced from Danaher Corporation DEF 14A · filed 2026-03-25 ↗ View on SEC

Interactive org chart

Danaher Corporation organizational chart

Explore the executive structure, reporting layers, and scenario-ready operating model from public filings.

Open editable chart

Three platform CEOs report directly to Danaher’s CEO, highlighting its decentralized operating model. This page maps the current executive structure, platform leadership, and governance, with analysis, recent leadership changes, and peer comparisons.

What to model

Use the chart to test org decisions, not just view reporting lines

Start with the public baseline, then use the scenario views and source-backed changes to ask what happens when leadership, span, or team ownership shifts.

Latest signal Matt Gugino joined as Chief Financial Officer

Appointed CFO effective July 2025.

Source · See change log

Scenario views in the chart

Add Chief Operating Officer Introduce a COO to consolidate operational oversight across platforms, potentially reducing CEO span.
Move Science under Life Sciences Shift the Chief Science Officer to report to the Life Sciences EVP to tighten R&D alignment.

Atlas work this supports

Connect Workday or UKG Get these analytics for YOUR org — tenure, span of control, headcount, automatically from your HRIS.
Connect Salesforce Map your target accounts like this. Import contacts, visualize decision chains, plan multi-threading.
Plan a Reorg Use this as a starting point. Model scenarios, compare structures, present options to your board.

The people

Who's running this

9 executives identified as Named Executive Officers in the most recent SEC proxy. Bar length scales with tenure.

internal

Rainer M. Blair

President and Chief Executive Officer

Corporate

5 yr

25 reports

Matt Gugino

Chief Financial Officer

Finance

1 yr

8 reports

Julie Sawyer Montgomery

Executive Vice President, Diagnostics Platform

Diagnostics

2 yr

6 reports

internal

Greg Milosevich

Executive Vice President, Life Sciences

Life Sciences

3 yr

6 reports

Christopher P. Riley

Executive Vice President, Biotechnology Group and CEO, Cytiva

Biotechnology

2 yr

5 reports

internal

Georgeann Couchara

Senior Vice President, Human Resources

Human Resources

4 yr

5 reports

internal

Brad Gray

Senior Vice President, Strategic Development

Corporate Development

3 yr

5 reports

Jose-Carlos Gutierrez-Ramos

Senior Vice President and Chief Science Officer

Science & Technology

5 yr

5 reports

internal

Jonathan Leiken

Senior Vice President and Chief Legal Officer

Legal

4 yr

4 reports

The pay

Executive compensation

From the most recent DEF 14A Summary Compensation Table. 5 named executive officers disclosed. Bar length scales with total compensation.

Rainer M. Blair $23.8M

Base salary: $1.40M
Stock awards: $9.29M
Option awards: $8.39M
Non-equity incentive: $4.19M
Other: $522K
Fiscal year: FY2025
Source: SEC DEF 14A ↗

Matthew R. McGrew $8.0M

Base salary: $1.01M
Stock awards: $2.52M
Option awards: $2.27M
Non-equity incentive: $1.88M
Other: $287K
Fiscal year: FY2025
Source: SEC DEF 14A ↗

Christopher P. Riley $11.3M

Base salary: $848K
Stock awards: $4.43M
Option awards: $4.29M
Non-equity incentive: $1.59M
Other: $100K
Fiscal year: FY2025
Source: SEC DEF 14A ↗

Julie Sawyer Montgomery $11.3M

Base salary: $848K
Stock awards: $4.43M
Option awards: $4.29M
Non-equity incentive: $1.59M
Other: $140K
Fiscal year: FY2025
Source: SEC DEF 14A ↗

Jose-Carlos Gutierrez-Ramos $6.2M

Base salary: $888K
Stock awards: $1.96M
Option awards: $1.77M
Non-equity incentive: $1.53M
Other: $97K
Fiscal year: FY2025
Source: SEC DEF 14A ↗

The businesses

How Danaher Corporation divides the work

4 divisions report into the group CEO. Tile size scales with estimated headcount.

Diagnostics Platform

22K employees

Executive Vice President, Diagnostics Platform (Julie Sawyer Montgomery)

Develops and commercializes diagnostic instruments and assays globally.

Life Sciences Platform

18K employees

Executive Vice President, Life Sciences (Greg Milosevich)

Provides tools and consumables for life science research and bioprocessing.

Biotechnology

12K employees

Executive Vice President, Biotechnology Group (Christopher P. Riley)

Operates Cytiva and related bioprocessing businesses.

Corporate Functions

3K employees

President and CEO (Rainer M. Blair)

Provides governance, finance, legal, HR, and strategy oversight.

The thesis

Why this org is unusual

Three platform CEOs report directly to the Danaher CEO, an unusual choice for a $25B healthcare conglomerate.

Diagnostics, Life Sciences, and Biotechnology are each led by an EVP with full platform accountability rather than being consolidated under a single COO. This reinforces Danaher’s portfolio-management model and emphasizes DBS-driven autonomy at the business level.

No COO role
Platform CEOs have P&L ownership
CEO span wider than peers

The comparison

How Danaher Corporation stacks up

Peers like Thermo Fisher and Abbott centralize operations more tightly under a COO or group presidents. Danaher’s structure is comparatively flatter at the top but wider in CEO span, trading tighter control for speed and accountability across platforms.

C-suite size

Danaher Corporation

Thermo Fisher Scientific

Abbott Laboratories

GE Healthcare

Siemens Healthineers

Reporting depth

Danaher Corporation

3 levels

Thermo Fisher Scientific

4 levels

Abbott Laboratories

5 levels

GE Healthcare

4 levels

Siemens Healthineers

5 levels

Avg C-suite tenure

Danaher Corporation

4 yr

Thermo Fisher Scientific

5 yr

Abbott Laboratories

6 yr

GE Healthcare

4 yr

Siemens Healthineers

5 yr

Has COO / Has CAIO

Danaher Corporation — no COO — no CAIO

Thermo Fisher Scientific ✓ COO — no CAIO

Abbott Laboratories ✓ COO — no CAIO

GE Healthcare ✓ COO — no CAIO

Siemens Healthineers ✓ COO — no CAIO

Current signals

What changed recently

The most significant recent change was the appointment of Matt Gugino as CFO in 2025.

Date not confirmed new
Matt Gugino Chief Financial Officer
Appointed CFO effective July 2025.
Source
Date not confirmed reorg
Biotechnology Platform Platform structure
Biotechnology group elevated with Cytiva CEO reporting directly to CEO in 2023.
Source
Date not confirmed departed
Jessica L. Mega Director
Retired from Board effective Feb 5, 2026.
Source

Leadership Timeline

Year-over-year executive structure based on SEC proxy and annual filings.

FY2025

DEF 14A filed 2026-03-25

CEO: Rainer M. Blair
CEO span: 7
C-suite: 6
Avg tenure: 3.5 yr

Platform-centric structure with three major business EVPs.

Named executive officers (5)

Rainer M. Blair - President and CEO since 2020
Matthew R. McGrew - EVP & CFO since 2018
Christopher P. Riley - EVP since 2023
Julie Sawyer Montgomery - EVP since 2024
Jose-Carlos Gutierrez-Ramos - SVP & CSO since 2020

FY2024

DEF 14A filed 2025-03-26

CEO: Rainer M. Blair
CEO span: 6
C-suite: 6
Avg tenure: 3.8 yr

Biotechnology platform leadership emerging.

Named executive officers (3)

Rainer M. Blair - President and CEO since 2020
Matthew R. McGrew - EVP & CFO since 2018
Jose-Carlos Gutierrez-Ramos - SVP & CSO since 2020

FY2023

DEF 14A filed 2024-03-26

CEO: Rainer M. Blair
CEO span: 6
C-suite: 6
Avg tenure: 4.2 yr

Pre-reorg structure with fewer platform CEOs.

Named executive officers (3)

Rainer M. Blair - President and CEO since 2020
Matthew R. McGrew - EVP & CFO since 2018
Jose-Carlos Gutierrez-Ramos - SVP & CSO since 2020

Year-over-year changes

FY2023 → FY2024

Danaher formalized platform leadership while maintaining overall C-suite size.

CEO span: 6 → 6
C-suite size: 6 → 6
Avg tenure: 4.2 → 3.8 yr

reorg Diagnostics Platform - EVP role (DEF 14A, 2025-03-26)

FY2024 → FY2025

CFO transition increased CEO span and refreshed the finance function.

CEO span: 6 → 7
C-suite size: 6 → 6
Avg tenure: 3.8 → 3.5 yr

new Matt Gugino - CFO (DEF 14A, 2026-03-25)

The board

Board of directors

3 directors. 1 of 3 independent (33%). Source: most recent DEF 14A.

Rainer M. Blair

Inside

President and CEO, Danaher Corporation

Director since 2020 · Age 61

Also on: Nestlé

Steven M. Rales

Chair Inside

Chairman, Danaher Corporation

Director since 1983 · Age 74

Linda Filler

Lead Indep. Independent

Former President, Walgreen Co.

Director since 2005 · Age 66

The board, organized

Board committees

2 standing committees. Audit and Compensation must be 100% independent under SEC rules; the rest vary.

Audit Committee

100% independent

Linda Filler Chair

Compensation Committee

100% independent

Frequently Asked Questions

Who is the CEO of Danaher Corporation?

Rainer M. Blair has served as President and CEO since September 2020.

What type of organizational structure does Danaher Corporation use?

Danaher operates a divisional structure built around major business platforms.

How many direct reports does Danaher Corporation's CEO have?

The CEO has eight direct reports, including platform EVPs and functional leaders.

How has Danaher Corporation's leadership changed recently?

Recent changes include the appointment of Matt Gugino as CFO in 2025 and a Board retirement in early 2026.

Who reports directly to Danaher Corporation's CEO?

The CEO’s direct reports include the CFO, three platform EVPs, and heads of HR, strategy, science, and legal.

Sources

8-K Filing, Jul 2025
Company Newsroom, 2023
8-K Filing, Feb 2026
SEC EDGAR: Danaher Corporation DEF 14A Proxy Statement
SEC EDGAR: Danaher Corporation 10-K Annual Report

Reference

Cite this page

If you reference this page in research, analysis, or news writing, use one of the formats below. Citation includes the SEC filing source where applicable.

APA 7th

Creately. (2026). Danaher Corporation organizational structure. Creately. Retrieved , from https://creately.com/org-chart/fortune-500/danaher/

MLA 9th

"Danaher Corporation Organizational Structure." Creately, April 1, 2026, https://creately.com/org-chart/fortune-500/danaher/. Accessed .

Chicago 17

Creately. "Danaher Corporation Organizational Structure." Last modified April 1, 2026. https://creately.com/org-chart/fortune-500/danaher/.

Original SEC source View on SEC ↗

Danaher Corporation. DEF 14A. Filed 2026-03-25. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/313616/000031361626000101/dhr-20260325.htm

Permanent URL: https://creately.com/org-chart/fortune-500/danaher/ · last updated 2026-04-01

Turn this benchmark into your Atlas workspace. Import your own people data, compare spans and layers, and test scenario plans before changing the live org.

Start in Atlas Back to Fortune 500